COVID-19 tweets from November 2020 have come back to haunt Pfizer once again. | COVID-19 tweets from November 2020 have come ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

The PMCPA also agreed with the complainant that Pfizer had not taken all possible steps to avoid similar breaches in its ...

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...

The deal comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital Markets ...

Astellas Pharma (ALPMY) and Pfizer (PFE) announced longer-term follow-up results from an open-label extension of the Phase 3 ...

The pharma giant entered an exclusive agreement with the Chinese biotech to gain rights to a cancer bispecific drug candidate.

US pharma major Pfizer (NYSE: PFE) is stepping up its presence in the high-stakes field of bispecific immuno-oncology with a ...

Pfizer’s stock surged up to 11 percent after the pharma giant reported a robust 85 percent year-on-year rise in net profit ...

BioSpace examines the busiest corporate venture capital arms in the pharmaceutical industry. Novo Holdings, which made ...

Drug prices in the United States are astronomical and climbing. Many analysts blame mergers and acquisitions among ...